Eiger Biopharmaceuticals (EIGR) Receives Media Sentiment Rating of 0.21

News coverage about Eiger Biopharmaceuticals (NASDAQ:EIGR) has trended somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Eiger Biopharmaceuticals earned a news sentiment score of 0.21 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.8831447294824 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the news stories that may have impacted Accern Sentiment’s rankings:

Eiger Biopharmaceuticals (NASDAQ:EIGR) traded up $0.65 during trading hours on Friday, hitting $16.00. The company had a trading volume of 205,550 shares, compared to its average volume of 93,820. The company has a debt-to-equity ratio of 1.19, a quick ratio of 5.78 and a current ratio of 5.78. The company has a market capitalization of $168.26, a P/E ratio of -3.02 and a beta of 2.54. Eiger Biopharmaceuticals has a fifty-two week low of $6.10 and a fifty-two week high of $16.20.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($1.10) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.28) by $0.18. research analysts anticipate that Eiger Biopharmaceuticals will post -4.56 EPS for the current year.

EIGR has been the subject of several recent analyst reports. Roth Capital initiated coverage on Eiger Biopharmaceuticals in a report on Thursday, October 19th. They issued a “buy” rating and a $35.00 price target for the company. Oppenheimer set a $34.00 price objective on Eiger Biopharmaceuticals and gave the stock a “buy” rating in a report on Thursday, December 7th. Zacks Investment Research upgraded Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a report on Monday, October 16th. ValuEngine upgraded Eiger Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Finally, Ladenburg Thalmann Financial Services initiated coverage on Eiger Biopharmaceuticals in a report on Wednesday, January 3rd. They set a “buy” rating and a $32.00 price objective for the company. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $30.63.

COPYRIGHT VIOLATION WARNING: “Eiger Biopharmaceuticals (EIGR) Receives Media Sentiment Rating of 0.21” was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.thelincolnianonline.com/2018/01/13/eiger-biopharmaceuticals-eigr-receives-media-sentiment-rating-of-0-21.html.

About Eiger Biopharmaceuticals

Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.

Insider Buying and Selling by Quarter for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply